A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19. (2022)
Attributed to:
New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3389/fmed.2022.956123
PubMed Identifier: 36160134
Publication URI: http://europepmc.org/abstract/MED/36160134
Type: Journal Article/Review
Volume: 9
Parent Publication: Frontiers in medicine
ISSN: 2296-858X